Bioptik Technology - Asset Resilience Ratio
Bioptik Technology (4161) has an Asset Resilience Ratio of 3.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Bioptik Technology (4161) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Bioptik Technology's Asset Resilience Ratio has changed over time. See Bioptik Technology net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bioptik Technology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bioptik Technology market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$49.08 Million | 3.12% |
| Total Liquid Assets | NT$49.08 Million | 3.12% |
Asset Resilience Insights
- Limited Liquidity: Bioptik Technology maintains only 3.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bioptik Technology Industry Peers by Asset Resilience Ratio
Compare Bioptik Technology's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Bioptik Technology (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Bioptik Technology.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.12% | NT$49.08 Million ≈ $1.55 Million |
NT$1.57 Billion ≈ $49.52 Million |
+0.32pp |
| 2024-12-31 | 2.80% | NT$41.63 Million ≈ $1.31 Million |
NT$1.49 Billion ≈ $46.87 Million |
+1.09pp |
| 2023-12-31 | 1.70% | NT$25.51 Million ≈ $803.83K |
NT$1.50 Billion ≈ $47.19 Million |
+0.25pp |
| 2022-12-31 | 1.46% | NT$22.08 Million ≈ $695.58K |
NT$1.52 Billion ≈ $47.74 Million |
-14.36pp |
| 2021-12-31 | 15.81% | NT$240.97 Million ≈ $7.59 Million |
NT$1.52 Billion ≈ $48.01 Million |
+5.52pp |
| 2020-12-31 | 10.29% | NT$151.71 Million ≈ $4.78 Million |
NT$1.47 Billion ≈ $46.43 Million |
+7.17pp |
| 2019-12-31 | 3.12% | NT$48.51 Million ≈ $1.53 Million |
NT$1.55 Billion ≈ $48.97 Million |
-16.95pp |
| 2018-12-31 | 20.07% | NT$321.95 Million ≈ $10.14 Million |
NT$1.60 Billion ≈ $50.53 Million |
+4.55pp |
| 2017-12-31 | 15.52% | NT$242.96 Million ≈ $7.65 Million |
NT$1.57 Billion ≈ $49.32 Million |
-- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more